HIGH

Carvedilol Tablets 12.5 mg Recall Expanded for NNCI Impurity Above FDA Limit (2025)

The FDA recalls 26,628 cartons of Carvedilol Tablets USP 12.5 mg distributed nationwide. The product fails CGMP standards due to NNCI impurity exceeding FDA limits. Stop using and contact The Harvard Drug Group LLC and Rugby Laboratories for guidance.

Quick Facts at a Glance

Recall Date
August 20, 2025
Hazard Level
HIGH
Brands
Major Pharmaceuticals, CARVEDILOL
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT

Hazard Information

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Carvedilol is a beta-blocker used to treat high blood pressure and heart failure. Manufacturers distribute in tablet form to patients nationwide.

Why This Is Dangerous

NNCI impurity above FDA limits could pose health risks; exact clinical implications depend on exposure and patient factors.

Industry Context

This recall is not described as part of a broader pattern in the provided data.

Real-World Impact

The recall requires patients and healthcare providers to review exposure, discontinue use where advised, and coordinate replacements or alternatives.

Practical Guidance

How to identify if yours is affected

  1. Check package for NDC 0904-7307-61
  2. Look for Lot T05693 and Exp. 03/2026
  3. Verify packaging indicates Major Pharmaceuticals and Rugby Laboratories

Where to find product info

FDA recall page linked in enforcement report; manufacturer letters to healthcare providers

What timeline to expect

Processing and guidance to be provided via recall letters; replacements or refunds depend on provider and distributor timelines

If the manufacturer is unresponsive

  • Escalate to FDA MedWatch
  • Contact state pharmacy board
  • Seek guidance from healthcare provider on alternatives

How to prevent similar issues

  • Verify NDC numbers before dispensing prescriptions
  • Monitor for NNCI-related recalls in drug databases
  • Keep patients informed about recall notices

Documentation advice

Keep recall letters, patient exposure records, and communications with pharmacy or provider as documentation

Product Details

Product: Carvedilol Tablets USP, 12.5 mg, 100-tablet carton. Packaged and distributed by Major Pharmaceuticals, Indianapolis, IN 46268, USA. NDC 0904-7307-61. Lot: T05693. Expiration: 03/2026. Quantity: 26,628 cartons. Distribution: Nationwide in the United States.

Reported Incidents

No specific patient incidents or injuries are detailed in the recall notice. Hazard is chemical impurity risk; no incident counts provided.

Key Facts

  • 26,628 cartons recalled
  • NDC 0904-7307-61
  • Lot T05693
  • Exp. Date 03/2026
  • NNCI impurity above 4.0 ppm
  • CGMP deviation

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANT
Injury Types
POISONINGOTHER

Product Details

Model Numbers
Lot #: T05693
Exp. Date 03/2026
UPC Codes
0904-7305
0904-7306
0904-7307
+5 more
Affected States
ALL
Report Date
August 27, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more